Insider activity at Galera Therapeutics, Inc. has been all selling for a year now: about $1,400 from one seller, and zero buyers in open-market trades.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | Sorensen Mel | CEO | Sell | 70,000 | $0.02 | $1K | SEC |
| Jan 2, 2025 | CHANG NANCY T | Director | Buy | 7,644,932 | $0.07 | $535K | SEC |
| Aug 20, 2024 | Sorensen Mel | CEO | Sell | 67,015 | $0.07 | $5K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 247,600 | $0.20 | $50K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 100,000 | $0.20 | $20K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 4,342 | $0.20 | $868 | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 100 | $0.19 | $19 | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 314 | $0.19 | $60 | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 215 | $0.19 | $41 | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 99,371 | $0.19 | $19K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 100,000 | $0.19 | $19K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 241,028 | $0.20 | $48K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 56,900 | $0.21 | $12K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 50,000 | $0.21 | $10K | SEC |
| May 1, 2024 | Schneid Yair | 10% Owner | Buy | 50,000 | $0.21 | $10K | SEC |
In the last 12 months Galera Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $1,400. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in GRTX was filed on 2025-11-24.
No congressional trades in GRTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).